Epirubicin is equivalent to adriamycin in vitro against many cancer cells but more effective against gastric cancer cells

S. Kohnoe, M. Yoshida, I. Takahashi, Y. Emi, Y. Maehara, K. Sugimachi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We compared the cytotoxic effects of two anthracycline derivatives, epirubicin (EPI) and adriamycin (ADM) against human tumor cells in vitro. Various tumor specimens obtained at surgery, included 57 liver, 19 lung, 16 gastric, 10 colorectal and 7 breast cancer specimens. These tumor cells were exposed to the same concentration of EPI or ADM for 3 days. The chemosensitivity of each tumor cell type to each drug was then assayed using the in vitro succinate dehydrogenase-inhibition (SDI) test. Sensitivity to the treatment was defined as a 50% or greater reduction in the succinate dehydrogenase (SD) activity of the tumor cells, relative to that of the control, (untreated) cells. Each cell type, except for gastric cancer cells, was equally sensitive to EPI and ADM. Gastric cancer cells were more sensitive to EPI than to ADM (P<0.05). The rate of coincidence, the sum of the co-sensitive and co-resistant rates of all the tumors, was quite high (90.8%). Thus, these findings indicate that EPI and ADM are equally cytotoxic to each tumor cell type, but EPI is more cytotoxic than ADM to gastric cancer cells. Since EPI is reported to be less cardiotoxic than ADM, EPI may replace ADM in cancer chemotherapy.

Original languageEnglish
Pages (from-to)389-392
Number of pages4
JournalAnticancer research
Volume12
Issue number2
Publication statusPublished - Jan 1 1992

Fingerprint

Epirubicin
Doxorubicin
Stomach Neoplasms
Neoplasms
Succinate Dehydrogenase
In Vitro Techniques
Anthracyclines
Stomach
Breast Neoplasms
Drug Therapy
Lung

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kohnoe, S., Yoshida, M., Takahashi, I., Emi, Y., Maehara, Y., & Sugimachi, K. (1992). Epirubicin is equivalent to adriamycin in vitro against many cancer cells but more effective against gastric cancer cells. Anticancer research, 12(2), 389-392.

Epirubicin is equivalent to adriamycin in vitro against many cancer cells but more effective against gastric cancer cells. / Kohnoe, S.; Yoshida, M.; Takahashi, I.; Emi, Y.; Maehara, Y.; Sugimachi, K.

In: Anticancer research, Vol. 12, No. 2, 01.01.1992, p. 389-392.

Research output: Contribution to journalArticle

Kohnoe, S, Yoshida, M, Takahashi, I, Emi, Y, Maehara, Y & Sugimachi, K 1992, 'Epirubicin is equivalent to adriamycin in vitro against many cancer cells but more effective against gastric cancer cells', Anticancer research, vol. 12, no. 2, pp. 389-392.
Kohnoe S, Yoshida M, Takahashi I, Emi Y, Maehara Y, Sugimachi K. Epirubicin is equivalent to adriamycin in vitro against many cancer cells but more effective against gastric cancer cells. Anticancer research. 1992 Jan 1;12(2):389-392.
Kohnoe, S. ; Yoshida, M. ; Takahashi, I. ; Emi, Y. ; Maehara, Y. ; Sugimachi, K. / Epirubicin is equivalent to adriamycin in vitro against many cancer cells but more effective against gastric cancer cells. In: Anticancer research. 1992 ; Vol. 12, No. 2. pp. 389-392.
@article{aab95528484549bb9afb409082c1fabf,
title = "Epirubicin is equivalent to adriamycin in vitro against many cancer cells but more effective against gastric cancer cells",
abstract = "We compared the cytotoxic effects of two anthracycline derivatives, epirubicin (EPI) and adriamycin (ADM) against human tumor cells in vitro. Various tumor specimens obtained at surgery, included 57 liver, 19 lung, 16 gastric, 10 colorectal and 7 breast cancer specimens. These tumor cells were exposed to the same concentration of EPI or ADM for 3 days. The chemosensitivity of each tumor cell type to each drug was then assayed using the in vitro succinate dehydrogenase-inhibition (SDI) test. Sensitivity to the treatment was defined as a 50{\%} or greater reduction in the succinate dehydrogenase (SD) activity of the tumor cells, relative to that of the control, (untreated) cells. Each cell type, except for gastric cancer cells, was equally sensitive to EPI and ADM. Gastric cancer cells were more sensitive to EPI than to ADM (P<0.05). The rate of coincidence, the sum of the co-sensitive and co-resistant rates of all the tumors, was quite high (90.8{\%}). Thus, these findings indicate that EPI and ADM are equally cytotoxic to each tumor cell type, but EPI is more cytotoxic than ADM to gastric cancer cells. Since EPI is reported to be less cardiotoxic than ADM, EPI may replace ADM in cancer chemotherapy.",
author = "S. Kohnoe and M. Yoshida and I. Takahashi and Y. Emi and Y. Maehara and K. Sugimachi",
year = "1992",
month = "1",
day = "1",
language = "English",
volume = "12",
pages = "389--392",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2",

}

TY - JOUR

T1 - Epirubicin is equivalent to adriamycin in vitro against many cancer cells but more effective against gastric cancer cells

AU - Kohnoe, S.

AU - Yoshida, M.

AU - Takahashi, I.

AU - Emi, Y.

AU - Maehara, Y.

AU - Sugimachi, K.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - We compared the cytotoxic effects of two anthracycline derivatives, epirubicin (EPI) and adriamycin (ADM) against human tumor cells in vitro. Various tumor specimens obtained at surgery, included 57 liver, 19 lung, 16 gastric, 10 colorectal and 7 breast cancer specimens. These tumor cells were exposed to the same concentration of EPI or ADM for 3 days. The chemosensitivity of each tumor cell type to each drug was then assayed using the in vitro succinate dehydrogenase-inhibition (SDI) test. Sensitivity to the treatment was defined as a 50% or greater reduction in the succinate dehydrogenase (SD) activity of the tumor cells, relative to that of the control, (untreated) cells. Each cell type, except for gastric cancer cells, was equally sensitive to EPI and ADM. Gastric cancer cells were more sensitive to EPI than to ADM (P<0.05). The rate of coincidence, the sum of the co-sensitive and co-resistant rates of all the tumors, was quite high (90.8%). Thus, these findings indicate that EPI and ADM are equally cytotoxic to each tumor cell type, but EPI is more cytotoxic than ADM to gastric cancer cells. Since EPI is reported to be less cardiotoxic than ADM, EPI may replace ADM in cancer chemotherapy.

AB - We compared the cytotoxic effects of two anthracycline derivatives, epirubicin (EPI) and adriamycin (ADM) against human tumor cells in vitro. Various tumor specimens obtained at surgery, included 57 liver, 19 lung, 16 gastric, 10 colorectal and 7 breast cancer specimens. These tumor cells were exposed to the same concentration of EPI or ADM for 3 days. The chemosensitivity of each tumor cell type to each drug was then assayed using the in vitro succinate dehydrogenase-inhibition (SDI) test. Sensitivity to the treatment was defined as a 50% or greater reduction in the succinate dehydrogenase (SD) activity of the tumor cells, relative to that of the control, (untreated) cells. Each cell type, except for gastric cancer cells, was equally sensitive to EPI and ADM. Gastric cancer cells were more sensitive to EPI than to ADM (P<0.05). The rate of coincidence, the sum of the co-sensitive and co-resistant rates of all the tumors, was quite high (90.8%). Thus, these findings indicate that EPI and ADM are equally cytotoxic to each tumor cell type, but EPI is more cytotoxic than ADM to gastric cancer cells. Since EPI is reported to be less cardiotoxic than ADM, EPI may replace ADM in cancer chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0026545495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026545495&partnerID=8YFLogxK

M3 - Article

C2 - 1580555

AN - SCOPUS:0026545495

VL - 12

SP - 389

EP - 392

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2

ER -